Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULSTER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULSTER.
SULFONAMIDES DUPLEX vs SULSTER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
2.5 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic